Mostrar el registro sencillo del ítem
dc.contributor.author
Masson, Walter
dc.contributor.author
Lobo, Martin
dc.contributor.author
Siniawski, Daniel A.
dc.contributor.author
Huerín, Melina S.
dc.contributor.author
Molinero, Graciela
dc.contributor.author
Valéro, René
dc.contributor.author
Nogueira, Juan Patricio
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.date.available
2019-08-07T20:03:17Z
dc.date.issued
2018-12
dc.identifier.citation
Masson, Walter; Lobo, Martin; Siniawski, Daniel A.; Huerín, Melina S.; Molinero, Graciela; et al.; Therapy with cholesteryl ester transfer protein (CETP) inhibitors and diabetes risk; Elsevier Masson; Diabetes & Metabolism; 44; 6; 12-2018; 508-513
dc.identifier.issn
1262-3636
dc.identifier.uri
http://hdl.handle.net/11336/81151
dc.description.abstract
Background: Cholesteryl ester transfer protein (CETP) inhibitors are a class of drugs that targets the CETP enzyme to significantly increase serum high-density lipoprotein cholesterol (HDL-C) and decrease low-density lipoprotein cholesterol (LDL-C) levels. As HDL-C has potential antidiabetic properties, and the beneficial effects of CETP drugs on glucose homoeostasis have not been sufficiently studied, the aims of this study were: (1) to evaluate the effect of CETP inhibitors on the incidence of diabetes; and (2) to assess the association between CETP inhibitor-induced changes in HDL-C levels and incidence of diabetes. Methods: A meta-analysis was performed of randomized controlled clinical trials of CETP inhibitor therapy, either alone or combined with other lipid-lowering drugs, reporting data from new cases of diabetes with a minimum of 6 months of follow-up, after searching the PubMed/MEDLINE, Embase and Cochrane Controlled Trials databases. A fixed-effects meta-regression model was then applied. Results: Four eligible trials of CETP inhibitors, involving a total of 73,479 patients, were considered for the analyses, including 960 newly diagnosed cases of diabetes in the CTEP inhibitor group vs 1086 in the placebo group. CETP inhibitor therapy was associated with a significant 12% reduction in incidence of diabetes (OR: 0.88, 95% CI: 0.81–0.96; P = 0.005). Assessment of the relationship between on-treatment HDL-C and the effect of CETP inhibitors showed a statistically non-significant trend (Z = –1.13, P = 0.26). Conclusion: CETP inhibitors reduced the incidence of diabetes. The improvement in glucose metabolism may have been related, at least in part, to the increase in HDL-C concentration.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Elsevier Masson
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.rights
info:eu-repo/semantics/openAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
dc.subject
Cholesteryl Ester Transfer Protein Inhibitors
dc.subject
High-Density Lipoprotein Cholesterol
dc.subject
Meta-Analysis
dc.subject
New-Onset Diabetes
dc.subject.classification
Endocrinología y Metabolismo
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
Medicina Clínica
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.title
Therapy with cholesteryl ester transfer protein (CETP) inhibitors and diabetes risk
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2019-08-01T20:11:24Z
dc.journal.volume
44
dc.journal.number
6
dc.journal.pagination
508-513
dc.journal.pais
Francia
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.journal.ciudad
Paris
dc.description.fil
Fil: Masson, Walter. Fundación Cardiológica Argentina; Argentina
dc.description.fil
Fil: Lobo, Martin. Fundación Cardiológica Argentina; Argentina
dc.description.fil
Fil: Siniawski, Daniel A.. Fundación Cardiológica Argentina; Argentina
dc.description.fil
Fil: Huerín, Melina S.. Fundación Cardiológica Argentina; Argentina
dc.description.fil
Fil: Molinero, Graciela. Fundación Cardiológica Argentina; Argentina
dc.description.fil
Fil: Valéro, René. Universite de la Mediterranee; Francia
dc.description.fil
Fil: Nogueira, Juan Patricio. Universidad Nacional de Formosa. Facultad de Ciencias de la Salud; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Nordeste; Argentina
dc.journal.title
Diabetes & Metabolism
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1016/j.diabet.2018.02.005
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S1262363618300454?via%3Dihub
Archivos asociados